Zenas BioPharma, Inc. (ZBIO) Financial Statements
Zenas BioPharma, Inc. (ZBIO) reported trailing twelve-month revenue of $1.0M (down 93.3% year on year) and net income of -$484.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$226.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ZBIOZenas BioPharma, Inc.Follow ZBIO — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 5.0 | 10.0 | 1.0 | |
| Research & development | 139.1 | 168.1 | 213.5 | |
| Operating income | -163.9 | -383.1 | -475.6 | |
| Pre-tax income | -156.6 | -377.8 | -484.2 | |
| Income tax | 0.4 | -0.1 | 0.2 | |
| Net income | -157.0 | -377.7 | -484.4 | |
| Diluted EPS ($) | -11.89 | -8.44 | -7.68 | |
| Diluted shares (mn) | 13.2 | 44.7 | — |
USD millions · SEC XBRL
Zenas BioPharma, Inc. — questions
- What is Zenas BioPharma, Inc.'s revenue?
- $1.0M over the twelve months to 2026-06-30, down 93.3% year on year, from its 10-Q and 10-K filings.
- What is Zenas BioPharma, Inc.'s net income?
- -$484.4M over the twelve months to 2026-06-30.
- What is Zenas BioPharma, Inc.'s free cash flow?
- -$226.0M over the twelve months to 2026-06-30.
- What are Zenas BioPharma, Inc.'s diluted earnings per share?
- $-7.68 over the twelve months to 2026-06-30.
Every figure on this page comes from Zenas BioPharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.